Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

计划入组 40 人 · 首次发布于 2026 年 2 月 18 日

M9466 in Combination with Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

计划入组 3 人 · 首次发布于 2024 年 7 月 19 日

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

计划入组 29 人 · 首次发布于 2020 年 8 月 17 日

DNA topoisomerase 1 inhibitors (cancer)

Topoisomerase inhibitor (Idorsia)

topoisomerase I inhibitor (sepsis)

NHI-1

United States

Xi'an No.1 Hospital

China

ALPHA-1 FOUNDATION, INC.

United States

FDA Grants Fast Track Designation to Mersana's Emiltatug Ledadotin for Expanded Breast Cancer Treatment

Zymeworks Receives FDA Clearance for ZW251, Novel Glypican-3 Targeted ADC for Hepatocellular Carcinoma

Sanofi-Pfizer CEACAM5 ADC Trial Halted in Europe as Merck KGaA Advances Competing Asset to Phase 3